The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...
In this study, researchers aimed to examine trends in nonsurgical management and other treatment modalities in low-risk, HR-positive DCIS.
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 ...
Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is typically ...
The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun ...
A cancer diagnosis often comes with overwhelming emotions and a flood of unfamiliar medical terms that can spark even more fear. But understanding these terms can help you feel more in control of your ...
Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients' blood, research from the University of Michigan and the ...
The patient is 44 years old, married for the past 20 years, with 3 teenage children. Before her first pregnancy, she had irregular periods. For the past 1 1/2 to 2 years, she has been getting only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results